Nanoparticle-based compositions

Abstract

Provided herein are new compositions including an inactivated pathogen and one or more adjuvant-loaded polymeric nanoparticles, wherein the adjuvant-loaded nanoparticles are bound to the inactivated pathogen. These compositions are useful for preventing and/or treating diseases caused by the specific pathogens, especially when administered to a subject's mucosal membranes.

1 - 79 . (canceled) 
     
     
         80 . A composition for stimulating a mucosal immune response against  Chlamydia trachomatis  in a human subject in need thereof, the composition comprising
 an inactivated form of  Chlamydia trachomatis,  and   one or more adjuvant-loaded polymeric nanoparticles, wherein the one or more adjuvant-loaded polymeric nanoparticles are each attached to the inactivated form of the  Chlamydia trachomatis,  and   wherein the one or more adjuvant-loaded polymeric nanoparticles comprise poly(lactic-co-glycolic acid)-block-poly(L-histidine)-block-poly(ethylene glycol) (PLGA-PLH-PEG) triblock copolymers.   
     
     
         81 . The composition of  claim 80 , wherein the composition is in a form suitable for mucosal administration. 
     
     
         82 . The composition of  claim 80 , wherein the mucosal route is selected from an ocular, an intranasal, an oral, a buccal, a sublingual, a tonsilar, a pulmonary, a gastric, an intestinal, a rectal, a vaginal, or an urinary tract route. 
     
     
         83 . The composition of  claim 80 , wherein the one or more adjuvant-loaded polymeric nanoparticles comprise an Endo-Porter peptide. 
     
     
         84 . The composition of  claim 80 , wherein the one or more adjuvant-loaded polymeric nanoparticles comprise a Toll-like receptor agonist. 
     
     
         85 . The composition of  claim 80 , wherein the one or more adjuvant-loaded polymeric nanoparticles are attached to the inactivated form of the  Chlamydia trachomatis  through electrostatic attraction or a linker. 
     
     
         86 . A composition for stimulating a mucosal immune response against a pathogen in a human subject in need thereof, the composition comprising
 a negatively charged inactivated form of the pathogen, and   one or more adjuvant-loaded polymeric nanoparticles having a positive charge, wherein the one or more adjuvant-loaded polymeric nanoparticles are each attached to the inactivated form of the pathogen through electrostatic attraction, and   wherein the one or more adjuvant-loaded polymeric nanoparticles comprise poly(lactic-co-glycolic acid)-block-poly(L-histidine)-block-poly(ethylene glycol) (PLGA-PLH-PEG) triblock copolymers.   
     
     
         87 . The composition of  claim 86 , wherein the pathogen is a bacterium, a virus, a parasite, or a fungus. 
     
     
         88 . The composition of  claim 86 , wherein the pathogen is selected from the group consisting of  Chlamydia trachomatis, Francisella tularensis, Mycobacterium tuberculosis, Streptococcus pneumoniae, Listeria monocytogenes, Vibrio cholera, Shigella sonnei, Shigella flexneri,  and  Salmonella typhimurium.    
     
     
         89 . The composition of  claim 86 , wherein the pathogen is a bacterium selected from the group consisting of  Actinomyces, Anabaena, Bacillus, Bacteroides, Bdellovibrio, Bordetella, Borrelia, Brucella, Campylobacter, Caulobacter, Chlamydia, Chlorobium, Chromatium, Clostridium, Corynebacterium, Cytophaga, Deinococcus, Enterococcus, Escherichia, Francisella, Halobacterium, Heliobacter, Haemophilus, Hyphomicrobium, Legionella, Leptspirosis, Listeria, Meningococcus A, B,  and  C, Methanobacterium, Micrococcus, Mycobacterium, Mycoplasma, Myxococcus, Neisseria, Nitrobacter, Oscillatoria, Prochloron, Proteus, Pseudomonas, Phodospirillum, Rickettsia, Salmonella, Shigella, Spirillum, Spirochaeta, Staphylococcus, Streptococcus, Streptomyces, Sulfolobus, Thermoplasma, Thiobacillus, Treponema, Vibrio,  and  Yersinia.    
     
     
         90 . The composition of  claim 86 , wherein the pathogen is  Chlamydia trachomatis.    
     
     
         91 . The composition of  claim 86 , wherein the pathogen is  Francisella tularensis.    
     
     
         92 . The composition of  claim 86 , wherein the pathogen is  Mycobacterium tuberculosis.    
     
     
         93 . The composition of  claim 86 , wherein the pathogen is a virus selected from the group consisting of  Adenoviridae, Arenaviridae, Arterivirus, Astroviridae, Baculoviridae, Badnavirus, Bamaviridae, Bimaviridae, Bromoviridae, Bunyaviridae, Caliciviridae, Capillovirus, Carlavirus, Caulimovirus, Circoviridae, Closterovirus, Comoviridae, Coronaviridae, Corticoviridae, Cystoviridae, Deltavirus, Dianthovirus, Enamovirus, Flaviviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Hypoviridae, Iridoviridae, Leviviridae, Lipothrixviridae, Microviridae, Orthomyxoviridae, Papillomaviridae, Papovaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Polyomaviridae, Poxviridae, Reoviridae, Retroviridae, Rhabdoviridae, Togaviridae,  and  Totiviridae.    
     
     
         94 . The composition of  claim 86 , wherein the pathogen is a human respiratory syncytial virus, a SARS coronavirus, a Norovirus, or a human immunodeficiency virus. 
     
     
         95 . The composition of  claim 86 , wherein the composition is in a form suitable for mucosal administration. 
     
     
         96 . The composition of  claim 86 , wherein the mucosal route is selected from an ocular, an intranasal, an oral, a buccal, a sublingual, a tonsilar, a pulmonary, a gastric, an intestinal, a rectal, a vaginal, or an urinary tract route. 
     
     
         97 . The composition of  claim 86 , wherein the one or more adjuvant-loaded polymeric nanoparticles comprise an Endo-Porter peptide. 
     
     
         98 . The composition of  claim 86 , wherein the one or more adjuvant-loaded polymeric nanoparticles comprise a Toll-like receptor agonist. 
     
     
         99 . The composition of  claim 98 , wherein the Toll-like receptor agonist is R848 or an unmethylated CpG oligodeoxynucleotide.